Preface content

Commercialisation of a recombinant vaccine against Boophilus microplus

Increasingly, there is need for methods to control cattle tick (Boophilus microplus) infestations by the use of non-chemical technology. This need is brought about by a mixture of market forces and the failure or inadequacy of existing technology. A recombinant vaccine has now been developed against the tick. This vaccine relies on the uptake with the blood meal of antibody directed against a critical protein in the tick gut. The isolation of the vaccine antigen, Bm86, and its production as a recombinant protein is briefly described. The vaccine has been tested in the field, has been taken through the full registration process and is now in commercial use in Australia. A related development has occurred in Cuba. The potential for improvement of the current vaccine and for the development of similar vaccines against other haematophagous parasites is discussed.

Call to action content

Newsletter

Trim content

Copyright: The Pirbright Institute 2014-2020 | A company limited by guarantee, registered in England no. 559784. The Institute is also a registered charity.

 

Site by Lightflows